Trump Administration Weighs Section 301 Probe of Drug Pricing in Germany, France and Japan
Updated
Updated · Fox News · Jun 3
Trump Administration Weighs Section 301 Probe of Drug Pricing in Germany, France and Japan
1 articles · Updated · Fox News · Jun 3
Summary
Section 301 action is under consideration as the Trump administration looks at whether foreign drug-pricing regimes unfairly burden U.S. commerce and American patients.
Germany, France, Japan and Switzerland are cited as using price caps, mandatory rebates and market controls that force manufacturers to accept lower returns or lose market access.
The argument for a probe is that those policies suppress global drug revenues, shift more research-and-development cost recovery onto the U.S. market, and leave Americans paying disproportionately high prices.
Germany’s April cost-containment push — including broader rebates and tighter price-volume rules — is presented as evidence the pressure is intensifying across major U.S. trading partners.
A formal investigation would give Washington a trade-law basis to challenge pharmaceutical pricing as a non-tariff barrier and fold the issue more directly into broader trade negotiations.